AR037826A1 - Derivados de piridazina fusionada - Google Patents

Derivados de piridazina fusionada

Info

Publication number
AR037826A1
AR037826A1 ARP020104845A ARP020104845A AR037826A1 AR 037826 A1 AR037826 A1 AR 037826A1 AR P020104845 A ARP020104845 A AR P020104845A AR P020104845 A ARP020104845 A AR P020104845A AR 037826 A1 AR037826 A1 AR 037826A1
Authority
AR
Argentina
Prior art keywords
nr4r5
alkyl
cycloalkyl
alkenyl
aryl
Prior art date
Application number
ARP020104845A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR037826A1 publication Critical patent/AR037826A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Los derivados de piridazina fusionada, que son útiles como inhibidores de CDK se describen en la presente. La presente descrita también incluye métodos para elaborar tales derivados de piridazinas fusionadas así como también métodos para utilizar los mismos en el tratamiento de enfermedades hiperproliferativas. Reivindicación 1: Un compuesto de la fórmula (1) o una sal, solvato o derivado fisiológicamente funcional del mismo, en donde: D es N o CH; R1 es hidrógeno, alquilo C1-6, alquenilo C2-4, alquinilo C2-4, alcoxi C1-3, halógeno, -CF3, hidroxi, ciano, -S(O)yalquilo C1-3, o -NR4R5; y es 0, 1 ó 2; a es 1 ó 2; R2 es hidrógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, cicloalquilo C3-7, halógeno, heterociclilo, arilo, heteroarilo, ciano, azido, nitro, -OR8, -OR6R8, -R6R7, -R6R'', -OS(O)2R9, -S(O)yR10, -C(O)R7, -C(O)OR7, -C(O)NR4R5, -N(H)R'C(=NR4)NR4R5, -OC(O)NR4R5, -OC(O)OR7, -C(=NR4)NR4R5, -NR4R5, -OC(O)R7 o -N(R8)C(O)R8; R3 es -(Q)p-(Q1), en donde Q es O, N(R8) o S(O)y, p es 0 ó 1; y es 0, 1 ó 2 y Q1 es alquilo C1-6, cicloalquilo C3-7, haloalquilo C1-6, arilo, arilo sustituido con -C(O)N(H)R6NR4R5 o -OC(H)(OH)R6NR4R6, heteroarilo, aralquilo, o R6NR4R5; R4 y R5 son independientemente hidrógeno, alquilo C1-3, cicloalquilo C3-7, -C(O)R9, o R4 y R5, junto con el átomo de nitrógeno al cual se unen, forman un heterociclilo; R6 es alquenilo, arileno, heteroarileno, cicloalquileno C3-7, alquenileno, cicloalquenileno C3-7, o alquinileno; R7 es hidrógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, -NR4R5, arilo, aralquilo, heteroarilo, cicloalquilo, heterociclilo, -S(O)yR10, -C(O)R8, -C(O)OR8, -C(O)NR4R5, -S(O)2NR4R5, -N(H)R'C(=NR4)NR4R5, -OC(O)NR4R5, -OC(O)OR8, -C(=NR4)NR4R5, -NR4R5, o -N(R8)C(O)R8; R8 es hidrógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, -NR4R5, arilo, aralquilo, heteroarilo, cicloalquilo, heterociclilo, o -S(O)2R9; R9 es alquilo C1-6 o haloalquilo C1-6; R10 es hidrógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, -NR4R5, arilo, aralquilo, heteroarilo, cicloalquilo, heterociclilo, -C(O)R8, -C(O)OR8, -C(O)NR4R5, -N(H)R'C(=NR4)NR4R5, -OC(O)NR4R5, -OC(O)OR8, -C(=NR4)NR4R5, -NR4R5, o -N(R8)C(O)R8; R' es alquileno C1-3 y R'' es -OR7, -OC(O)NR4R5, -OC(O)OR7, o -OC(O)R7.
ARP020104845A 2001-12-17 2002-12-13 Derivados de piridazina fusionada AR037826A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34179801P 2001-12-17 2001-12-17

Publications (1)

Publication Number Publication Date
AR037826A1 true AR037826A1 (es) 2004-12-09

Family

ID=23339081

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104845A AR037826A1 (es) 2001-12-17 2002-12-13 Derivados de piridazina fusionada

Country Status (10)

Country Link
US (1) US7279473B2 (es)
EP (1) EP1463730B1 (es)
JP (1) JP2005524609A (es)
AR (1) AR037826A1 (es)
AT (1) ATE323706T1 (es)
AU (1) AU2002357164A1 (es)
DE (1) DE60210819T2 (es)
ES (1) ES2262899T3 (es)
TW (1) TW200301119A (es)
WO (1) WO2003051886A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062236A1 (en) 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
AU2003301302A1 (en) * 2002-10-15 2004-05-04 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
EP1648889B1 (en) * 2003-07-11 2008-10-29 Warner-Lambert Company LLC Isethionate salt of a selective cdk4 inhibitor
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
EP1928237A4 (en) 2005-09-02 2011-03-09 Abbott Lab NEW HETEROCYCLES BASED ON IMIDAZO
AU2007328981B2 (en) * 2006-12-08 2013-07-11 F. Hoffmann-La Roche Ag Substituted pyrimidines and their use as JNK modulators
CA2707989A1 (en) * 2007-12-07 2009-06-11 Novartis Ag Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
NZ587589A (en) 2008-02-15 2012-10-26 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
ES2538135T3 (es) * 2008-06-30 2015-06-17 Janssen Pharmaceutica N.V. Proceso para la preparación de derivados sustituidos de pirimidina
AR074870A1 (es) * 2008-12-24 2011-02-16 Palau Pharma Sa Derivados de pirazolo (1,5-a ) piridina
JP5959537B2 (ja) * 2011-01-28 2016-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリジニル−ピリミジン及び医薬としてのその使用
US20150203812A1 (en) * 2014-01-20 2015-07-23 Francesco Tombola Inhibitors of Voltage Gated Ion Channels
GB201605126D0 (en) * 2016-03-24 2016-05-11 Univ Nottingham Inhibitors and their uses
CN106699608A (zh) * 2016-12-26 2017-05-24 常州大学 一种含有强吸电子基团的苯胍及其盐的制备方法
GB201715342D0 (en) 2017-09-22 2017-11-08 Univ Nottingham Compounds
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU622330B2 (en) * 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
JP2002501532A (ja) * 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
YU11900A (sh) * 1997-09-05 2002-11-15 Glaxo Group Limited Derivati 2,3-diaril-pirazolo (1,5-b) piridazina, njihovo dobijanje i njihova upotreba kao inhibitora ciklooksigenaze 2(cox-2)
AU3352899A (en) 1997-12-11 1999-07-12 American Home Products Corporation 2,4,6-trisubstituted pyridines with estrogenic activity and methods for the solid phase synthesis thereof
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
SK9892001A3 (en) 1999-11-10 2002-04-04 Ortho Mcneil Pharm Inc Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods
AU2001292670A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
AU2002357164A8 (en) 2003-06-30
EP1463730B1 (en) 2006-04-19
DE60210819D1 (en) 2006-05-24
WO2003051886A8 (en) 2004-08-19
AU2002357164A1 (en) 2003-06-30
WO2003051886A1 (en) 2003-06-26
US7279473B2 (en) 2007-10-09
DE60210819T2 (de) 2007-04-19
ES2262899T3 (es) 2006-12-01
US20050090507A1 (en) 2005-04-28
ATE323706T1 (de) 2006-05-15
TW200301119A (en) 2003-07-01
JP2005524609A (ja) 2005-08-18
EP1463730A1 (en) 2004-10-06

Similar Documents

Publication Publication Date Title
AR037826A1 (es) Derivados de piridazina fusionada
ES2502490T3 (es) Compuestos aminoheteroarílicos como inhibidores de proteín quinasas
NZ543897A (en) Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
BRPI0718700B8 (pt) Heterodímeros de ácido glutâmico, e kit
AR050186A1 (es) Derivados de amino-piperidina, su preparacion y su aplicacion en terapeutica.
CY1110676T1 (el) ΠΥΡΑΖΟΛΟ[3,4-b]ΠΥΡΙΔΙΝΙΚΕΣ ΕΝΩΣΕΙΣ, ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΦΩΣΦΟΔΙΕΣΤΕΡΑΣΗΣ
AR038834A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4; composiciones farmaceuticas que los contienen; proceso de preparacion del compuesto y uso del mismo para fabricar un farmaco
HUP0303538A2 (hu) Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények
ATE490788T1 (de) Antivirale phosphonate analoge
CY1111295T1 (el) Παραγωγα πυριμιδινης χρησιμα για τη θεραπεια ασθενειων που προκαλουνται απο crth2
PA8558001A1 (es) Derivados de isonicotin y nicotinamida de benzotiazoles
AR048289A1 (es) Eteres de anillos imidazo sulfona sustituidos.
AR077267A1 (es) Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
AR036832A1 (es) Compuestos derivados de himbacina, agonistas receptores de trombina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de medicamentos
BRPI0509910A (pt) derivados do amino-ftalazina, o respectivo reparo e a sua aplicação em terapêutica
AR046046A1 (es) Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
AR036103A1 (es) Imidazotriazinas, procedimiento para su preparacion, uso de dichos compuestos para la manufactura de un medicamento para enfermedades neurodegenerativas y dicho medicamento
CO6150145A2 (es) Derivados de aril/heterociclo/cicloalquil/cicloalquil fenil substituidos utiles como agentes inmunosupresores
AR037797A1 (es) Combinacion de inhibidores de proteasa dependientes del citocromo p450
BR0313846A (pt) Derivados de dioxano-2-alquilcarbamatos, sua preparação e sua aplicação em terapêutica
HUP0401638A2 (hu) Daganatellenes hatású tiofén- és tiazolszulfonamid származékok, valamint ezeket tartalmazó gyógyászati készítmények
RU2010130418A (ru) Производные 4-аминопиримидина
UY29023A1 (es) Procedimiento de preparacinn de derivados n- piperidino - 1, 5 - difenilpirazol - 3 - carboxamida.-
AR039988A1 (es) Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos
AR073565A1 (es) Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure